Section Arrow
DCTH.NASDAQ
- Delcath Systems
Quotes are at least 15-min delayed:2026/01/22 17:00 EST
After Hours
Last
 11.17
+0.19 (+1.73%)
Bid
10.87
Ask
11.25
High 11.17 
Low 10.98 
Volume 2.67K 
Regular Hours (Closed)
Last
 10.98
+0.64 (+6.19%)
Day High 
11.15 
Prev. Close
10.34 
1-M High
10.86 
Volume 
532.73K 
Bid
10.87
Ask
11.25
Day Low
10.35 
Open
10.37 
1-M Low
9.69 
Market Cap 
358.80M 
Currency 美元 
P/E 344.67 
%Yield -- 
10-SMA 10.33 
20-SMA 10.26 
50-SMA 9.73 
52-W High 18.23 
52-W Low 8.12 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.03/1.32
Enterprise Value
359.73M
Balance Sheet
Book Value Per Share
3.31
Cash Flow
Cash Flow Yield
0.03
Income Statement
Total Revenue
37.21M
Operating Revenue Per Share
0.08
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ABTAbbott Laboratories108.61-12.12-10.04%15.3PE
After Hours 109.05 +0.44 +0.41%
BSXBoston Scientific Corp91.29-0.42-0.46%49.04PE
After Hours 90.9 -0.39 -0.43%
DXCMDexCom73.92+1.81+2.51%39.94PE
After Hours 73.92 0 0.00%
PACBPacific Biosciences of California2.67+0.25+10.33%-- 
After Hours 2.66 -0.01 -0.37%
MDTMedtronic plc101.34+1.05+1.05%27.2PE
After Hours 101.34 0 0.00%
Industry overview quotes are at least 15 minutes delayed
Business Description
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS,is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.